Endocrinology and Metabolism10.3803/enm.2021.13532022372233-242Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular DiseaseSangmo Hong, Woo Je Lee, Cheol-Young Park,,
10.21203/ of aspirin versus cilostazol for inhibition of antiplatelet aggregation in type 2 diabetes mellitus patients (ESCORT-DM Study)Sangmo Hong, Woo Je Lee, Cheol-Young Park,
Current Cardiovascular Risk Reports10.1007/s12170-011-0207-z20116162-70Aspirin and Other Antiplatelet Agents and Their Effects on Cardiovascular Disease in Type 2 DiabetesC. D. Williams, M. S. Kirkman,,
The Journal of Clinical Pharmacology10.1177/0091270005280377200545101172-1178Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy SubjectsJ. Jermany, J. Branson, R. Schmouder, M. Guillaume, C. Rordorf,
Pharmacoepidemiology and Drug Safety10.1002/pds.1828200918121143-1149Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage studyLennart Welin, Lars Wilhelmsen, Arne Björnberg, Anders Odén,,
JACC: Cardiovascular Interventions10.1016/j.jcin.2014.12.011201582S2CRT-225 Outside Start Cilostazol Bridge Study (Outpatient peri-Surgical Interruption of Drug Eluting Stent Antiplatelet Regimen Testing A Cilostazol Bridge Study): A 6 year experienceCharles L. Laham, Michael S. Chandra, Nicolas W. Shammas,
Catheterization and Cardiovascular Interventions10.1002/ccd.24416201281142-49Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus statusPiera Capranzano, Jose Luis Ferreiro, Masafumi Ueno, Davide Capodanno, Kodlipet Dharmashankar, Andrew Darlington, Bhaloo Desai, Antonio Tello-Montoliu, Fabiana Rollini, Dominick J. Angiolillo,
Catheterization and Cardiovascular Interventions10.1002/ccd.21995200974S1S1-S6Combination antiplatelet therapy in patients with peripheral arterial disease: Is the best therapy aspirin, clopidogrel, or both?Emile R. Mohler,
European Heart Journal10.1093/eurheartj/ehz748.0676201940Supplement_1P1929A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular diseaseT.-H Chao, S.-Y Tseng, P.-Y Liu, Y.-H Li,
Diabetes10.2337/db18-417-p201867Supplement_1The Effects of Cardiovascular Risk Factor Combined Antiplatelet Therapy and the Risk of Cerebrovascular Events in Patients with T2DM in an Urban Community over 96-Month Follow-Up—The Beijing Communities Diabetes Study 19XUE LIAN ZHANG, SHEN YUAN YUAN, BCDS GROUP,